<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00636467</url>
  </required_header>
  <id_info>
    <org_study_id>GAS2PLUS</org_study_id>
    <secondary_id>ET2007-045</secondary_id>
    <nct_id>NCT00636467</nct_id>
  </id_info>
  <brief_title>Axillary Sentinel Lymph Node Detection in Breast Cancers &gt; 2 cm</brief_title>
  <acronym>GAS2PLUS</acronym>
  <official_title>Evaluation of the Technique of Axillary Sentinel Lymph Node (SLN) Detection in Breast Cancers &gt; 2 cm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PHRC 2007: financial support</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the quality criteria of the SLN detection technique
      in breast cancer patients with a tumor size (clinical measurement) greater than 2 centimeters
      (rate of false negatives, rate of detection).

      Eligible patients will only be registered (no randomization). The estimated inclusion period
      is approximately 24 months. The duration of the research is 25 months (24 months for patient
      inclusion + 1 month for reception of results). The maximum participation duration of each
      patient is 1 month.

      The number of patients required in this multicentric and prospective study is 240 (16
      participating centers).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Axillary node extension is one of the major prognostic factors in breast cancer. Axillary
      dissection of Berg level I and II nodes is the validated method to obtain information on
      lymph node invasion, but it is associated with important morbidity.

      Sentinel lymph node assessment (SLN) was developed to select patients likely not to have
      axillary node extension using a technique less invasive than conventional dissection.
      Axillary dissection is restricted to patients with undetected or metastatic SLN.

      SLN detection involves subareolar or peri-tumoral injection of lymphotropic contrast agents
      which map the regional lymphatic drainage pattern of the tumor.

      This technique allows an optimization of histopathological analysis: the pathologist must
      analyze only two nodes on average (instead of 10-15), allowing the examination of numerous
      tissue sections and the development of specific techniques such as immunohistochemistry.

      The principal indicators of success for the technique are the detection rate, the false
      negative rate and the number of SLN sampled.

      The assessment of feasibility is based on concomitant histopathological analysis of the SLN
      and of complementary lymph nodes.

      There is no consensus in the literature on the SLN technique to be used for tumors with
      clinical size superior to 2 cm in diameter.

      The aim of this prospective, multicentric study is to evaluate the performance of the SLN
      technique, in terms of detection rate and false negative rate, for patients with tumors
      greater than 2 cm (clinical measurement).

      A homogeneous technique with &quot;combined&quot;, colorimetric and isotopic SLN detection with
      subareolar or peri-tumoral injection will be used. This consensus &quot;combined&quot; technique has
      been validated by all investigators. The histopathological procedure will also be
      homogeneous, and validated within the group of pathologists of the Fédération Nationale des
      Centres de Lutte Contre le Cancer (FNCLCC). Breast surgery will either be a mastectomy or
      conservative treatment.

      The primary objective of the study is to evaluate the quality criteria of the SLN detection
      technique in breast cancer patients with a tumor size (clinical measurement) greater than 2
      centimeters (rate of false negatives, rate of detection).

      The secondary objectives are:

        -  Evaluation of the number of SLN sampled per patient,

        -  Lymphoscintigraphic evaluation of the pattern of lymphatic drainage in breast tumors &gt; 2
           centimeters,

        -  Precise histopathological description of the SLN sampled and of axillary nodes of levels
           I and II.

      Evaluation criteria:

      The primary criterion is the rate of false negatives, determined by the ratio of the number
      of patients with detected but negative SLN to the total number of positive non-sentinel nodes
      at the time of axillary dissection of levels I and II (patients classified as N+ according to
      the TNM system).

      This rate will be determined after calculation of the detection rate, determined by the ratio
      of the number of patients evaluated on the total number of patients.

      In agreement with international recommendations, the expected rate of false negatives should
      be &lt; 5 % with a detection rate &gt; 85 %.

      Secondary criteria include:

        -  Total number of sampled SLN per patient,

        -  Lymphoscintigraphy: detection of SLN by means of extra-axillary markings,

        -  Histopathological results:

             -  SLN: metastases, capsular breach, micro metastases, isolated cells,

             -  Dissection: number of positive nodes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality criteria of the SLN detection technique</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of sampled SLN per patient</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of SLN by means of extra-axillary markings (lymphoscintigraphy)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological results (SLN)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological results (dissection)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>No label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of Nanocis® or Nanocoll® (Tc-colloid) on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No name</intervention_name>
    <description>Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)</description>
    <arm_group_label>No label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, age ≥ 18 years

          -  Patient with invasive unifocal breast cancer with tumor size &gt; 2 cm at initial
             examination (clinical examination and/or imaging)

          -  Preoperative histological diagnosis of infiltrating mammary carcinoma

          -  No lymph node at clinical examination

          -  No treatment for this cancer before surgery

          -  Mandatory affiliation with a social security system

          -  Written, signed informed consent

        Exclusion Criteria:

          -  No invasive breast cancer

          -  Breast tumor =&lt; 2 cm

          -  Preoperative histological diagnosis other than infiltrating mammary carcinoma

          -  Multifocal breast cancer

          -  Inflammatory breast cancer

          -  Metastatic cancer

          -  History of homolateral breast surgery

          -  History of allergic disorders

          -  History of homolateral breast cancer

          -  Difficult follow-up

          -  Pregnant or lactating woman

          -  Previous inclusion in the trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé MIGNOTTE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard, Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Boulogne sur Mer</name>
      <address>
        <city>Boulogne Sur Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Calais</name>
      <address>
        <city>Calais</city>
        <zip>62107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des 2 Caps</name>
      <address>
        <city>Coquelles</city>
        <zip>62231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Acacias</name>
      <address>
        <city>Cucq</city>
        <zip>62780</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Guilherand Granges</city>
        <zip>07500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Arrondissement Montreuil sur Mer</name>
      <address>
        <city>Rang Du Fliers</city>
        <zip>62180</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMCO</name>
      <address>
        <city>Saint Martin Boulogne</city>
        <zip>62280</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995 Apr 6;332(14):901-6.</citation>
    <PMID>7877646</PMID>
  </reference>
  <reference>
    <citation>Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity from complete axillary dissection. Br J Cancer. 1992 Jul;66(1):136-8.</citation>
    <PMID>1637663</PMID>
  </reference>
  <reference>
    <citation>Ververs JM, Roumen RM, Vingerhoets AJ, Vreugdenhil G, Coebergh JW, Crommelin MA, Luiten EJ, Repelaer van Driel OJ, Schijven M, Wissing JC, Voogd AC. Risk, severity and predictors of physical and psychological morbidity after axillary lymph node dissection for breast cancer. Eur J Cancer. 2001 May;37(8):991-9.</citation>
    <PMID>11334724</PMID>
  </reference>
  <reference>
    <citation>Kissin MW, Querci della Rovere G, Easton D, Westbury G. Risk of lymphoedema following the treatment of breast cancer. Br J Surg. 1986 Jul;73(7):580-4.</citation>
    <PMID>3730795</PMID>
  </reference>
  <reference>
    <citation>Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401.</citation>
    <PMID>8092905</PMID>
  </reference>
  <reference>
    <citation>Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol. 1993 Dec;2(6):335-9; discussion 340.</citation>
    <PMID>8130940</PMID>
  </reference>
  <reference>
    <citation>Glass EC, Essner R, Giuliano AE. Sentinel node localization in breast cancer. Semin Nucl Med. 1999 Jan;29(1):57-68. Review.</citation>
    <PMID>9990684</PMID>
  </reference>
  <reference>
    <citation>Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997 Sep;226(3):271-6; discussion 276-8.</citation>
    <PMID>9339933</PMID>
  </reference>
  <reference>
    <citation>McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, Vennekotter DJ, Turk PS, Tate PS, Sardi A, Cerrito PB, Edwards MJ. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000 Jul;18(13):2560-6.</citation>
    <PMID>10893287</PMID>
  </reference>
  <reference>
    <citation>Weaver DL, Krag DN, Ashikaga T, Harlow SP, O'Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer. 2000 Mar 1;88(5):1099-107.</citation>
    <PMID>10699901</PMID>
  </reference>
  <reference>
    <citation>Tafra L, McMasters KM, Whitworth P, Edwards MJ. Credentialing issues with sentinel lymph node staging for breast cancer. Am J Surg. 2000 Oct;180(4):268-73.</citation>
    <PMID>11113433</PMID>
  </reference>
  <reference>
    <citation>McMasters KM, Wong SL, Chao C, Woo C, Tuttle TM, Noyes RD, Carlson DJ, Laidley AL, McGlothin TQ, Ley PB, Brown CM, Glaser RL, Pennington RE, Turk PS, Simpson D, Edwards MJ; University of Louisville Breast Cancer Study Group. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg. 2001 Sep;234(3):292-9; discussion 299-300.</citation>
    <PMID>11524582</PMID>
  </reference>
  <reference>
    <citation>Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999 Jul;134(7):764-7. Review.</citation>
    <PMID>10401830</PMID>
  </reference>
  <reference>
    <citation>Bedrosian I, Reynolds C, Mick R, Callans LS, Grant CS, Donohue JH, Farley DR, Heller R, Conant E, Orel SG, Lawton T, Fraker DL, Czerniecki BJ. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 2000 Jun 1;88(11):2540-5.</citation>
    <PMID>10861431</PMID>
  </reference>
  <reference>
    <citation>Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (&gt; or = 5 cm) invasive breast cancer. Ann Surg Oncol. 2001 Oct;8(9):688-92.</citation>
    <PMID>11597008</PMID>
  </reference>
  <reference>
    <citation>Lelievre L, Houvenaeghel G, Buttarelli M, Brenot-Rossi I, Huiart L, Tallet A, Tarpin C, Jacquemier J. Value of the sentinel lymph node procedure in patients with large size breast cancer. Ann Surg Oncol. 2007 Feb;14(2):621-6. Epub 2006 Nov 12.</citation>
    <PMID>17103062</PMID>
  </reference>
  <reference>
    <citation>Schwartz GF, Giuliano AE, Veronesi U; Consensus Conference Committee. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002 May 15;94(10):2542-51. Review.</citation>
    <PMID>12173319</PMID>
  </reference>
  <reference>
    <citation>Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP; American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 20;23(30):7703-20. Epub 2005 Sep 12.</citation>
    <PMID>16157938</PMID>
  </reference>
  <results_reference>
    <citation>Edwards M, Giuliano A, Reintgen D, Tafra L. Consensus statement on guidelines for performance of sentinel lymph node biopsy for breast cancer. Am Soc Breast Surg Q. Press Release, 1998 ;Fall :3</citation>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>March 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2008</study_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer (tumors&gt; 2 cm)</keyword>
  <keyword>Detection</keyword>
  <keyword>Axillary sentinel lymph node</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

